Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Operating Expenses for 16 consecutive years, with $18.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 3.94% to $18.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.9 million through Dec 2025, down 7.7% year-over-year, with the annual reading at $74.9 million for FY2025, 7.7% down from the prior year.
  • Operating Expenses for Q4 2025 was $18.5 million at Anika Therapeutics, down from $18.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $35.4 million in Q1 2023, with the low at -$18.9 million in Q4 2023.
  • Average Operating Expenses over 5 years is $19.4 million, with a median of $20.6 million recorded in 2021.
  • The sharpest move saw Operating Expenses plummeted 146.33% in 2022, then surged 194.2% in 2024.
  • Over 5 years, Operating Expenses stood at $27.3 million in 2021, then tumbled by 146.33% to -$12.6 million in 2022, then crashed by 49.9% to -$18.9 million in 2023, then skyrocketed by 194.2% to $17.8 million in 2024, then grew by 3.94% to $18.5 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $18.5 million, $18.8 million, and $18.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.